PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
43.89%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
30.11%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
108.64%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
108.64%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
935.79%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
104.86%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
104.86%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.01%
Share count expansion well above CVE's 0.03%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.01%
Diluted share reduction more than 1.5x CVE's 0.11%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
1.99%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
-9.26%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-52.66%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
15.95%
10Y revenue/share CAGR under 50% of CVE's 64.10%. Michael Burry would suspect a lasting competitive disadvantage.
-40.32%
Negative 5Y CAGR while CVE stands at 64.10%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-3.52%
Negative 3Y CAGR while CVE stands at 27.23%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-17.95%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-73.84%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-48.28%
Negative 3Y OCF/share CAGR while CVE stands at 18.13%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
790.84%
Net income/share CAGR above 1.5x CVE's 247.76% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
11281.02%
5Y net income/share CAGR above 1.5x CVE's 247.76%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2224.02%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-1.96%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-61.43%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-43.08%
Negative 3Y equity/share growth while CVE is at 15.04%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
41.88%
Dividend/share CAGR of 41.88% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-82.77%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-65.53%
Negative near-term dividend growth while CVE invests at 33.50%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-0.08%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-100.00%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
13.95%
Asset growth above 1.5x CVE's 1.29%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
37.06%
BV/share growth above 1.5x CVE's 2.99%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.84%
We’re deleveraging while CVE stands at 4.53%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-11.85%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.